Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP) - PubMed (original) (raw)
Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP)
K Forslind et al. Ann Rheum Dis. 2004 Sep.
Abstract
Objective: To investigate the role of anti-cyclic citrullinated peptide antibody (anti-CCP) for the prediction of radiological outcome in patients with early rheumatoid arthritis.
Methods: Anti-CCP was assessed at baseline in 379 patients with early rheumatoid arthritis (disease duration <1 year). Radiological joint damage and progression were assessed by Larsen score after two years of follow up (end point) and used as outcome variables. The prognostic value of anti-CCP and other demographic and disease related baseline variables were assessed by univariate and multivariate analyses, including calculation of odds ratios (OR), predictive values, and multiple logistic regression models.
Results: The presence of anti-CCP was associated with significantly higher Larsen score both at baseline and at end point. Univariate predictor analysis showed that anti-CCP had the highest significant OR for radiological joint damage and progression after baseline Larsen score, followed by rheumatoid factor, erythrocyte sedimentation rate (ESR), C reactive protein, age, smoking status, and sex. In stepwise multiple regression analyses, baseline Larsen score, anti-CCP, and ESR were selected as significant independent predictors of the radiological outcomes.
Conclusions: There is good evidence for an association of anti-CCP with radiological joint changes in rheumatoid arthritis. Anti-CCP is an independent predictor of radiological damage and progression. Though prediction in early rheumatoid arthritis is still far from perfect, the use of anti-CCP in clinical practice should make it easier for rheumatologists to reach judicious treatment decisions.
Similar articles
- Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.
Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, Rantapää-Dahlqvist S. Berglin E, et al. Ann Rheum Dis. 2006 Apr;65(4):453-8. doi: 10.1136/ard.2005.041376. Epub 2005 Sep 21. Ann Rheum Dis. 2006. PMID: 16176994 Free PMC article. - Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis.
Kaltenhäuser S, Pierer M, Arnold S, Kamprad M, Baerwald C, Häntzschel H, Wagner U. Kaltenhäuser S, et al. Rheumatology (Oxford). 2007 Jan;46(1):100-4. doi: 10.1093/rheumatology/kel052. Epub 2006 May 25. Rheumatology (Oxford). 2007. PMID: 16728439 - The value of HLA-DRB1 shared epitope, -308 tumor necrosis factor-alpha gene promoter polymorphism, rheumatoid factor, anti-citrullinated peptide antibodies, and early erosions for predicting radiological outcome in recent-onset rheumatoid arthritis.
Reneses S, González-Escribano MF, Fernández-Suárez A, Pestana L, Davila B, Wichmann I, García A. Reneses S, et al. J Rheumatol. 2009 Jun;36(6):1143-9. doi: 10.3899/jrheum.081075. Epub 2009 May 1. J Rheumatol. 2009. PMID: 19411391 - Reliable and cost-effective serodiagnosis of rheumatoid arthritis.
Meyer PW, Ally MM, Anderson R. Meyer PW, et al. Rheumatol Int. 2016 Jun;36(6):751-8. doi: 10.1007/s00296-016-3433-3. Epub 2016 Feb 9. Rheumatol Int. 2016. PMID: 26856871 Review.
Cited by
- Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display.
Araujo GR, Vaz ER, Fujimura PT, Fonseca JE, de Lima LM, Canhão H, Venturini G, Cardozo KH, Carvalho VM, Napimoga MH, Goulart LR, Gonçalves J, Ueira-Vieira C. Araujo GR, et al. Arthritis Res Ther. 2015 Jun 23;17(1):168. doi: 10.1186/s13075-015-0685-3. Arthritis Res Ther. 2015. PMID: 26099944 Free PMC article. - Autoantibodies in Rheumatoid Arthritis - Laboratory and Clinical Perspectives.
Rönnelid J, Turesson C, Kastbom A. Rönnelid J, et al. Front Immunol. 2021 May 14;12:685312. doi: 10.3389/fimmu.2021.685312. eCollection 2021. Front Immunol. 2021. PMID: 34054878 Free PMC article. Review. - The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, Chou CT. Chen HA, et al. Ann Rheum Dis. 2006 Jan;65(1):35-9. doi: 10.1136/ard.2005.038851. Epub 2005 Jun 23. Ann Rheum Dis. 2006. PMID: 15975966 Free PMC article. Clinical Trial. - Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
Lie BA, Viken MK, Odegård S, van der Heijde D, Landewé R, Uhlig T, Kvien TK. Lie BA, et al. Ann Rheum Dis. 2007 Dec;66(12):1604-9. doi: 10.1136/ard.2006.067892. Epub 2007 May 1. Ann Rheum Dis. 2007. PMID: 17472988 Free PMC article. - EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM, Klareskog L, Machold K, Martin-Mola E, Nielsen H, Silman A, Smolen J, Yazici H. Combe B, et al. Ann Rheum Dis. 2007 Jan;66(1):34-45. doi: 10.1136/ard.2005.044354. Epub 2006 Jan 5. Ann Rheum Dis. 2007. PMID: 16396980 Free PMC article.
References
- Arthritis Rheum. 2000 Jan;43(1):155-63 - PubMed
- Arthritis Rheum. 2002 Feb;46(2):357-65 - PubMed
- Arthritis Rheum. 2000 Aug;43(8):1831-5 - PubMed
- Rheumatology (Oxford). 2000 Sep;39(9):939-49 - PubMed
- Rheumatology (Oxford). 2000 Sep;39(9):1031-6 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous